Cargando…
Protocol for LAsting Symptoms after Oesophageal Resectional Surgery (LASORS): multicentre validation cohort study
INTRODUCTION: Surgery is the primary curative treatment for oesophageal cancer, with considerable recent improvements in long-term survival. However, surgery has a long-lasting impact on patient’s health-related quality of life (HRQOL). Through a multicentre European study, our research group was ab...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279661/ https://www.ncbi.nlm.nih.gov/pubmed/32499265 http://dx.doi.org/10.1136/bmjopen-2019-034897 |
_version_ | 1783543611043872768 |
---|---|
author | Markar, Sheraz Rehan Griffiths, Ewen A Behrens, Paul Singh, Pritam Vohra, Ravi S Gossage, James Underwood, Tim Hanna, George B |
author_facet | Markar, Sheraz Rehan Griffiths, Ewen A Behrens, Paul Singh, Pritam Vohra, Ravi S Gossage, James Underwood, Tim Hanna, George B |
author_sort | Markar, Sheraz Rehan |
collection | PubMed |
description | INTRODUCTION: Surgery is the primary curative treatment for oesophageal cancer, with considerable recent improvements in long-term survival. However, surgery has a long-lasting impact on patient’s health-related quality of life (HRQOL). Through a multicentre European study, our research group was able to identify key symptoms that affect patient’s HRQOL. These symptoms were combined to produce a tool to identify poor HRQOL following oesophagectomy (LAsting Symptoms after Oesophageal Resection (LASOR) tool). The objective of this multicentre study is to validate a six-symptom clinical tool to identify patients with poor HRQOL for use in everyday clinical practice. METHODS AND ANALYSIS: Included patients will: (1) be aged 18 years or older, (2) have undergone an oesophagectomy for cancer between 2015 and 2019, and (3) be at least 12 months after the completion of adjuvant oncological treatments. Patients will be given the previously created LASOR questionnaire. Each symptom from the LASOR questionnaire will be graded according to impact on quality of life and frequency of the symptom, with a composite score from 0 to 5. The previously developed LASOR symptom tool will be validated against HRQOL as measured by the European Organisation for Research and Treatment of Cancer QLQC30 and OG25. SAMPLE SIZE: With a predicted prevalence of poor HRQOL of 45%, based on the previously generated LASOR clinical symptom tool, to validate this tool with a sensitivity and specificity of 80%, respectively, a minimum of 640 patients will need to be recruited to the study. ETHICS AND DISSEMINATION: NHS Health Research Authority (North East—York Research Ethics Committee) approval was gained 8 November 2019 (REC reference 19/NE/0352). Multiple platforms will be used for the dissemination of the research data, including international clinical and patient group presentations and publication of research outputs in a high impact clinical journal. |
format | Online Article Text |
id | pubmed-7279661 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-72796612020-06-15 Protocol for LAsting Symptoms after Oesophageal Resectional Surgery (LASORS): multicentre validation cohort study Markar, Sheraz Rehan Griffiths, Ewen A Behrens, Paul Singh, Pritam Vohra, Ravi S Gossage, James Underwood, Tim Hanna, George B BMJ Open Surgery INTRODUCTION: Surgery is the primary curative treatment for oesophageal cancer, with considerable recent improvements in long-term survival. However, surgery has a long-lasting impact on patient’s health-related quality of life (HRQOL). Through a multicentre European study, our research group was able to identify key symptoms that affect patient’s HRQOL. These symptoms were combined to produce a tool to identify poor HRQOL following oesophagectomy (LAsting Symptoms after Oesophageal Resection (LASOR) tool). The objective of this multicentre study is to validate a six-symptom clinical tool to identify patients with poor HRQOL for use in everyday clinical practice. METHODS AND ANALYSIS: Included patients will: (1) be aged 18 years or older, (2) have undergone an oesophagectomy for cancer between 2015 and 2019, and (3) be at least 12 months after the completion of adjuvant oncological treatments. Patients will be given the previously created LASOR questionnaire. Each symptom from the LASOR questionnaire will be graded according to impact on quality of life and frequency of the symptom, with a composite score from 0 to 5. The previously developed LASOR symptom tool will be validated against HRQOL as measured by the European Organisation for Research and Treatment of Cancer QLQC30 and OG25. SAMPLE SIZE: With a predicted prevalence of poor HRQOL of 45%, based on the previously generated LASOR clinical symptom tool, to validate this tool with a sensitivity and specificity of 80%, respectively, a minimum of 640 patients will need to be recruited to the study. ETHICS AND DISSEMINATION: NHS Health Research Authority (North East—York Research Ethics Committee) approval was gained 8 November 2019 (REC reference 19/NE/0352). Multiple platforms will be used for the dissemination of the research data, including international clinical and patient group presentations and publication of research outputs in a high impact clinical journal. BMJ Publishing Group 2020-06-03 /pmc/articles/PMC7279661/ /pubmed/32499265 http://dx.doi.org/10.1136/bmjopen-2019-034897 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Surgery Markar, Sheraz Rehan Griffiths, Ewen A Behrens, Paul Singh, Pritam Vohra, Ravi S Gossage, James Underwood, Tim Hanna, George B Protocol for LAsting Symptoms after Oesophageal Resectional Surgery (LASORS): multicentre validation cohort study |
title | Protocol for LAsting Symptoms after Oesophageal Resectional Surgery (LASORS): multicentre validation cohort study |
title_full | Protocol for LAsting Symptoms after Oesophageal Resectional Surgery (LASORS): multicentre validation cohort study |
title_fullStr | Protocol for LAsting Symptoms after Oesophageal Resectional Surgery (LASORS): multicentre validation cohort study |
title_full_unstemmed | Protocol for LAsting Symptoms after Oesophageal Resectional Surgery (LASORS): multicentre validation cohort study |
title_short | Protocol for LAsting Symptoms after Oesophageal Resectional Surgery (LASORS): multicentre validation cohort study |
title_sort | protocol for lasting symptoms after oesophageal resectional surgery (lasors): multicentre validation cohort study |
topic | Surgery |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279661/ https://www.ncbi.nlm.nih.gov/pubmed/32499265 http://dx.doi.org/10.1136/bmjopen-2019-034897 |
work_keys_str_mv | AT markarsherazrehan protocolforlastingsymptomsafteroesophagealresectionalsurgerylasorsmulticentrevalidationcohortstudy AT griffithsewena protocolforlastingsymptomsafteroesophagealresectionalsurgerylasorsmulticentrevalidationcohortstudy AT behrenspaul protocolforlastingsymptomsafteroesophagealresectionalsurgerylasorsmulticentrevalidationcohortstudy AT singhpritam protocolforlastingsymptomsafteroesophagealresectionalsurgerylasorsmulticentrevalidationcohortstudy AT vohraravis protocolforlastingsymptomsafteroesophagealresectionalsurgerylasorsmulticentrevalidationcohortstudy AT gossagejames protocolforlastingsymptomsafteroesophagealresectionalsurgerylasorsmulticentrevalidationcohortstudy AT underwoodtim protocolforlastingsymptomsafteroesophagealresectionalsurgerylasorsmulticentrevalidationcohortstudy AT hannageorgeb protocolforlastingsymptomsafteroesophagealresectionalsurgerylasorsmulticentrevalidationcohortstudy AT protocolforlastingsymptomsafteroesophagealresectionalsurgerylasorsmulticentrevalidationcohortstudy |